| Literature DB >> 33710806 |
Meina Jiang1,2, Shuai Fang1,2, Xiaodong Zhao1,3, Chengwei Zhou1,3, Zhaohui Gong1,2.
Abstract
The epithelial-mesenchymal transition (EMT) is a highly complex phenotypic conversion during embryogenesis, and is important for metastasis, which contributes to tumor deterioration and poor prognoses of cancer patients. Lung carcinoma has a high tendency to develop the EMT. Circular RNAs (circRNAs) are involved in EMT-related cell invasion and metastasis in various types of cancers. Moreover, circRNAs have been found to be a link to EMT-related transcription factors and EMT-associated signaling pathways. This review mainly focuses on the influence of EMT-related circRNAs on lung carcinomas. More specifically, the roles of EMT-inducing and EMT-suppressive circRNAs in lung carcinomas are discussed. With circRNAs potentially becoming promising biomarkers and therapeutic targets for cancer managements, they will hopefully stimulate the interest of medical workers in the early diagnosis, personalized treatment, and positive prognoses in the era of precision oncology.Entities:
Keywords: Epithelial-mesenchymal transition; circular RNA; lung carcinoma; metastasis; transcription factor
Year: 2021 PMID: 33710806 PMCID: PMC8185863 DOI: 10.20892/j.issn.2095-3941.2020.0238
Source DB: PubMed Journal: Cancer Biol Med ISSN: 2095-3941 Impact factor: 4.248
CircRNAs modulating the epithelial-mesenchymal transition (EMT) in various carcinomas
| Cancer type | CircRNA | Function | Mechanism | Reference |
|---|---|---|---|---|
| HCC | circCul2 (hsa_circ_10720) | Promoted EMT | Twist1 promoted vimentin expression and EMT by increasing levels of circCul2, which can absorb miRNAs that target vimentin | [ |
| UCB | circPRMT5 (circRNA_101320) | Promoted EMT and aggressiveness | By circPRMT5/miR-30c/SNAIL1/E-cadherin pathway | [ |
| Melanoma | circRNA_0084043 | Promoted growth and metastasis | By circRNA_0084043/miR-153-3p/Snail axis | [ |
| Cervical cancer | circRNA_000284 | Promoted proliferation and cell invasion | By circRNA_000284/miR-506/Snail 2 axis | [ |
| PTC | circNUP214 (hsa_ circ_0089153) | Promoted proliferation, migration and invasion | By circNUP214/miR-145/ZEB2 axis | [ |
| TNBC | circANKS1B (hsa_circ_0007294) | Promoted EMT and metastasis | By circANKS1B/miR-152-3p, miR-148a-3p/USF1/TGF-β1/Smad signaling and a positive feedback loop of USF1/circANKS1B | [ |
| OSCC | circUHRF1 (hsa_circ_0002185) | Promoted proliferation, metastasis, invasion and EMT | By a positive feedback loop of circUHRF1/miR-526b-5p/c-Myc/TGF-β1/ESRP1/circUHRF1 | [ |
| CRC | circRNA_100290 | Promoted metastasis and EMT | By circRNA_100290/miR-516b/FZD4/Wnt/β-catenin signaling pathway | [ |
| ccRCC | circAKT3 | Inhibited metastasis and EMT | By circAKT3/miR-296-3p/E-cadherin pathway | [ |
| DLBCL | circAPC (hsa_circ_0127621) | Hindered cell proliferation | By circAPC/APC/TET1/Wnt/β-catenin signaling pathway | [ |
| CRC | hsa_circ_0026344 | Functioned as anti-tumor molecule | By hsa_circ_0026344/miR-183/Wnt/β-catenin signaling pathway | [ |
| Bladder cancer | circPTK2 (hsa_circ_0003221) | Enhanced migration | Unknown | [ |
| CRC | circPTK2 (hsa_circ_0005273) | Stimulated EMT | Attaching to vimentin protein at sites Ser38, Ser55, Ser82 | [ |
HCC, hepatocellular carcinoma; UCB, urothelial carcinoma of the bladder; PTC, papillary thyroid cancer; TNBC, triple-negative breast cancer; OSCC, oral squamous cell carcinoma; CRC, colorectal cancer; ccRCC, clear cell renal cell carcinoma; DLBCL, diffuse large B-cell lymphoma.
The epithelial-mesenchymal transition (EMT)-related circRNAs in lung carcinoma
| Type | CircRNA | Target/pathway |
|---|---|---|
| EMT-inducing circRNAs in NSCLC | circ-ENO1 | circ-ENO1/miR-223p/ENO1 axis |
| circAGFG1 | circAGFG1/miR-203/ZNF281 axis | |
| circP4HB | circP4HB/miR-133a-5p/vimentin pathway | |
| hsa_circ_0007534 | Unknown | |
| hsa_circ_0079530 | Unknown | |
| circ_0067934 | Unknown | |
| circRNA CCDC66 | HGF and c-Met upregulate circRNA CCDC66, nAchRα7 downregulates circRNA CCDDC 66 | |
| circ_0012673 | circ_0012673/miR-320A/LIMK1 axis | |
| hsa_circ_000984 | Wnt/β-catenin pathway | |
| circ_001569 | transcription factor 4 and Wnt/β-catenin pathway | |
| circ-SOX4 (hsa_circ_0131457) | circ-SOX4/miR-1270/PLAGL2/Wnt signaling pathway | |
| EMT-suppressive circRNAs in NSCLC | circPTK2 (hsa_circ_0008305) | circPTK2/miR-429/miR-200b-3p/Snail axis |
| circPTPRA (hsa_circ_102984) | circPTPRA/miR-96-5p/RASSF8/E-cadherin | |
| hsa_circ_0007059 | hsa_circ_0007059/miR-378/Wnt/β-catenin pathway and ERK1/2 pathway | |
| circ_0006427 | circ_0006427/miR-6783e3p/DKK1/Wnt/β-catenin pathway | |
| EMT-suppressive circRNAs in SCLC | cESRP1 | cESRP1/miR-93-5p/Smad7/p21(CDKN1A) axis |
ENO1, enolase 1; AGFG1, ArfGAP with FG repeats 1; ZNF281, zinc finger protein 281; P4HB, prolyl 4-hydroxylase subunit beta; CCDC66, coiled-coil domain containing 66; HGF, hepatocyte growth factor; nAchRα7, nicotinic acetylcholine receptor Alpha 7; LIMK1, LIM domain kinase 1; SOX4, SRY-box transcription factor 4; PTK2, protein tyrosine kinase 2; PTPRA, protein tyrosine phosphatase receptor type A; RASSF8, Ras association domain family member 8; DKK1, Dickkopf WNT signaling pathway inhibitor 1; EMT, epithelial mesenchymal transition; NSCLC, non-small cell lung cancer.